Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 19/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3558532 | 0.92 | SLC6A9 (0.55) | SLC6A9 | |
| SCHEMBL5039803 | 0.87 | SLC6A9 (0.60) | SLC6A9 | |
| SCHEMBL759527 | 0.86 | SLC6A9 (0.59) | SLC6A9 | |
| SCHEMBL3558262 | 0.82 | SLC6A9 (0.56) | SLC6A9 | |
| SCHEMBL2903171 | 0.81 | SLC6A9 (0.67) | SLC6A9 | |
| SCHEMBL760752 | 0.80 | SLC6A9 (0.54) | SLC6A9 | |
| SCHEMBL757871 | 0.79 | SLC6A9 (0.86) | SLC6A9 | |
| SCHEMBL761703 | 0.78 | SLC6A9 (0.52) | SLC6A9 | |
| SCHEMBL3561478 | 0.78 | SLC6A9 (0.58) | SLC6A9 | |
| SCHEMBL2896463 | 0.77 | SLC6A9 (0.68) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1942733-B1 | RADIOLABELED GLYCINE TRANSPORTER INHIBITORS | MERCK SHARP & DOHME (US) | 2012-03-21 | — | — | EP | disclosed |
| US-7834031-B2 | Radiolabeled glycine transporter inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090269278-A1 | Radiolabeled Glycine Trasporter Inhibitors | MERCK SHARP & DOHME LLC | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090269278-A1 | Radiolabeled Glycine Trasporter Inhibitors | SLC6A5, SLC1A5, SLC1A3 | SLC6A9 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.